Isogenica, Biolauncher, Cresset in Discovery Platform Pact

Isogenica, Biolauncher and Cresset Biomolecular Discovery have formed a collaborative joint venture to develop an innovative end-to-end therapeutic discovery platform. The parties will integrate their expertise in peptide library design, evolutionary screening, next generation sequencing, structural analytics and molecular field-based computational chemistry to identify active compounds against high-value therapeutic targets.
 
The new approach harnesses the vast chemical and conformational diversity of very large (1014) peptide libraries to explore available chemical space around a novel biological target. Enrichment of the peptide libraries towards greater specificity for the target is driven by an advanced computational biology system that is also used to identify the active conformations of populations of binding peptides. These binding peptide conformations can then be translated into a high quality field pharmacophore (a drug template) and used to identify drug-like small molecules for testing. This integrated set of technologies represents a unique platform that can rapidly and cost effectively progress a drug target to structurally diverse small molecule drug leads without recourse to high throughput screening, according to an Isogenica statement.
 
Elements of the platform have been proven by the parties in collaboration with their respective customers. The approach has been shown to be compatible with both extracellular and intracellular targets enabling a large proportion of the druggable genome to be evaluated. The next step is to validate the joint venture’s approach with third party drug targets.
 
According to Isogenica, the alliance “illustrates how innovative companies are adapting to the changing pharmaceutical research and development business and the current equity funding gap.”
 
Kevin Matthews, chief executive officer, Isogenica, commented, “We are excited by the potential to integrate cutting edge molecular biology with state-of-the-art computational biology and chemistry tools to develop small molecule drugs against novel targets using the combined expertise of the businesses. The industry needs to leverage the significant investment in individual platform technologies to address the innovation gap and deliver shareholder value from therapeutic research and development.”
 
“A willingness to collaborate across the partners to deliver proof of concept developments has created a unique opportunity for us to link our world-leading technologies into a platform that can create significant value and opportunities for our underlying businesses,” said Rowan Gardner, chairman, Biolauncher.
 
“By integrating Cresset’s field-based computational chemistry into this platform we will be able to apply our proven approach to more targets and demonstrate how we can find diverse small molecule leads against a range of pharmaceutically interesting new targets” said Rob Scoffin, chief executive officer, Cresset Biomolecular Discovery.